No-reflow: Again prevention is better than treatment

European Heart Journal

Volumn 31, Issue 20, 2010, Pages

  Niccoli, Giampaolo ^a   Kharbanda, Rajesh K ^b   Crea, Filippo ^a   Banning, Adrian P ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE; ATRIAL NATRIURETIC FACTOR; CARIPORIDE; CARVEDILOL; CYCLOSPORIN; ENIPORIDE; FOSINOPRIL; NICORANDIL; NITROPRUSSIDE SODIUM; PEXELIZUMAB; VALSARTAN;

ARTICLE; BLOOD CLOT LYSIS; CONTRAST ENHANCEMENT; ECHOCARDIOGRAPHY; HEART PROTECTION; HUMAN; NO REFLOW PHENOMENON; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT INDICATION;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; HUMANS; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; NEUTROPHILS; NO-REFLOW PHENOMENON; VASODILATOR AGENTS;

EID: 77958116813     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq299     Document Type: Article

References (67)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous throm-bolytic therapy for acute myocardial infarction: a quantitative review of 23 ran-domised trials. Lancet 2003;361:13-20.
2. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimen-tal laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2008;72:950-957.
3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
4. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009;54:281-292.
5. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006;101:359-372.
6. Duilio C, Ambrosio G, Kuppusamy P, DiPaula A, Becker LC, Zweier JL Neutro-phils are primary source of O2 radicals during reperfusion after prolonged myo-cardial ischemia. Am J Physiol Heart Circ Physiol 2001;280:H2649-H2657.
7. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol 2009;193:215-269.
8. Bullough DA, Magill MJ, Firestein GS, Mullane KM. Adenosine activates A2 recep-tors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J Immunol 1995;155:2579-2586.
9. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F. Ration-ale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007;23: 57-63.
10. Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler Thromb Vasc Biol 2007;27:2258-2265.
11. Niccoli G, Spaziani C, Marino M, Pontecorvo ML, Cosentino N, Bacà M, Porto I, Leone AM, Crea F. Effect of chronic aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction. Am J Cardiol 2010;105:587-591.
12. Collet JP, Montalescot G. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diab Vasc Dis Res 2005;2: 136-143.
13. Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation 1987;75:292-298.
14. Vignali L, Talanas G, Saia F, Menozzi A, Cattabiani MA, Solinas E, Rubboli A, Repetto A, Medda M, Emanuele A, Ardissino D. Genetic association between the 1976T-C polymorphism in the adenosine A2 receptor and angiographic no-reflow phenomenon (abstr). Il giornale italiano di Cardiologia Invasiva 2007; 3(Suppl. 1):109.
15. Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, Cheng JL, Gao RL. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron Artery Dis 2006;17:463-469.
16. Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K The myocardial Na +-H+ exchange: structure, regulation, and its role in heart disease. Circ Res 1999;85:777-786.
17. Théroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, Tognoni G, White HD, Willerson JT, Jessel A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation 2000;102:3032-3038.
18. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schröder R, Tiemann R, Machnig T, Neuhaus KL, ESCAMI Investigators. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapyfor acute myocardial infarction: results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial. J Am Coll Cardiol 2001;38:1644-1650.
19. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary ade-nosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-2159.
20. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ, Jessurun GA, Anthonio RL, van den Heuvel AF, Tan ES, Zijlstra F. Effect of high-dose intracoronaryadenosine administration during primary percutaneous coron-ary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv 2009;2:323-329.
21. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, Weinstein JM, Wolak A, Ilia R, Zahger D. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006;152:e9-e14.
22. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, Matsubara T Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005;112: 1284-1288.
23. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, Nishikawa N, Higashino Y, Fujii K, Minamino T. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarc-tion. J Am Coll Cardiol 1997;30:1193-1199.
24. APEX AMI Investigators, Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Van de Werf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary per-cutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297: 43-51.
25. Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, Butter C, Grip L, Hansen PR, Süselbeck T, Clemmensen PM, Marin-Galiano M, Geudelin B, Buser PT, F.I.R.E. Investigators. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Pre-vention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009;53:720-729.
26. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S;,J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370:1483-1493.
27. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
28. Ito H, Tomooka T, Sakai N. Lack of myocardial perfusion immediately after suc-cessful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992;85:1699-1705.
29. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008;358: 557-567.
30. Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G. Coronary microembolization. Basic Res Cardiol 2006;101:373-382.
31. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E, TIMI Study Group. Combination therapy with abcixi-mab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001;103:2550-2554.
32. Petronio AS, De Carlo M, Ciabatti N, Amoroso G, Limbruno U, Palagi C, Di Bello V, Romano MF, Mariani M. Left ventricular remodeling after primary coron-ary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J 2005;150: 1015.
33. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007;28:443-449.
34. Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intrave-nous bolus abciximab application in patients with ST-elevation myocardial infarc-tion undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008;118:49-57.
35. Deibele AJ,Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoron-ary Eptifibatide Bolus administration during percutaneous coronary revasculariza-tion for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the intracoronary Eptifibatide (ICE) trial. Circulation 2010;121:784-791.
36. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, Kuroda T, Tanaka K, Masuyama T, Hori M, Fujii K Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7. (Pubitemid 36044395)
37. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:56-65.
38. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, Inoue K, Fujii K Chronic pre-treatment ofstatins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006;27:534-539.
39. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv 2008;7: 283-289.
40. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-1720.
41. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW, AMISTAD-II Inves-tigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780.
42. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, Pironi B, Capasso M, Richichi G. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005;95:1358-1361.
43. Airoldi F, Briguori C, Cianflone D, Cosgrave J, Stankovic G, Godino C, Carlino M, Chieffo A, Montorfano M, Mussardo M, Michev I, Colombo A, Maseri A. Fre-quency of slow coronary flow following successful stent implantation and effect of nitroprusside. Am J Cardiol 2007;99:916-920.
44. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, Hori M, Higashino Y, Fujii K, Minamino T Intravenous nicorandil can preserve microvascu-lar integrity and myocardial viability in patients with reperfused anterior wall myo-cardial infarction. J Am Coll Cardiol 1999;33:654-660.
45. Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H, Fujita N, Sasaki S, Matsunaga T, Okumura K Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percu-taneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J 2004;148:E15.
46. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57:444-451.
47. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989;80:1846-1861.
48. Rochitte CE, Lima JA, Bluemke DA, Reeder SB, McVeigh ER, Furuta T, Becker LC, Melin JA. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998;98:1006-1014.
49. Selvanayagam JB, Cheng AS, Jerosch-Herold M, Rahimi K, Porto I, van Gaal W, Channon KM, Neubauer S, Banning AP. Effect of distal embolization on myocar-dial perfusion reserve after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study. Circulation 2007;116:1458-1464.
50. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, Rebuzzi AG, Crea F. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 2003;89:731-737.
51. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physi-ologyto clinical cardiology. Physiol Rev2003;83:1113-1151.
52. Peart JN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am J Physiol Heart Circ Physiol 2009;296:H1705-H1720.
53. Jerome SN, Akimitsu T, Gute DC, Korthuis RJ. Ischemic preconditioning attenu-ates capillary no-reflow induced by prolonged ischemia and reperfusion. Am J Physiol 1995;268:H2063-H2067.
54. Posa A, Pavo N, Hemetsberger R, Csonka C, Csont T, Ferdinandy P, Petrási Z, Varga C, Pavo IJ, Laszlo FJr, Huber K, Gyöngyösi M. Protective effect of ischaemic preconditioning on ischaemia/reperfusion-induced microvascular obstruction determined by on-line measurements of coronary pressure and blood flow in pigs. Thromb Haemost 2010;103:450-460.
55. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A, Chiariello L, Gioffrè PA. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994;90:700-705.
56. Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, Rongen GA. Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol 2006;48: 700-707.
57. Niccoli G, Altamura L, Fabretti A, Lanza GA, Biasucci LM, Rebuzzi AG, Leone AM, Porto I, Burzotta F, Trani C, Crea F. Ethanol abolishes ischemic preconditioning in humans. JAm Coll Cardiol 2008;51:271-275.
58. Ambrosio G, Del Pinto M, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, Anderson FA, Gore JM, López-Sendón J, Wyman A, Kennelly BM, Fox KA, GRACE Investigators. Chronic nitrate therapy is associated with different presen-tation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 2010;31:430-438.
59. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister R. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002; 106:2881-2883.
60. Kharbanda RK, Nielsen TT, Redington AN. Translation of remote ischaemic pre-conditioning into clinical practice. Lancet 2009;374:1557-1565.
61. Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375: 727-734.
62. Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, Panagopoulou V, Tsarouchas K, Vavetsi S, Pyrgakis V, Deftereos S. Cardioprotec-tive role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action.JACC Cardiovasc Interv 2010;3:49-55.
63. Shimizu M, Saxena P, Konstantinov IE, Cherepanov V, Cheung MM, Wearden P, Zhangdong H, Schmidt M, Downey GP, Redington AN. Remote ischemic precon-ditioning decreases adhesion and selectively modifies functional responses of human neutrophils. J Surg Res 2010;158:155-161.
64. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief cor-onary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004;44:1103-1110.
65. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 2009;204:334-341.
66. Hansen PR, Thibault H, Abdulla J. Postconditioning during primary percutaneous coronary intervention: a review and meta-analysis. Int J Cardiol 2009; doi:10.1016/j.ijcard.2009.03.118. Published online ahead of print 5 May 2009.
67. Lønborg J, Kelbaek H, Vejlstrup N, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Treiman M, Jensen JS, Engstrøm T. Cardioprotective effects of ischemic postconditioning in patients treated with primary percuta-neous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv 2010;3:34-41.